News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

With New Owners, Ambrx, Inc. Aims To Challenge Genentech (RHHBY)



11/3/2016 7:44:23 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The young Chinese venture-capital backed biotech company Ambrx has received some good news recently. In August, it secured a $45 million round of financing led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund.

The same month, it received approval for its Investigational New Drug (IND) from the Food and Drug Administration to start clinical trials in the USA for its novel HER2 targeting antibody drug conjugate(ADC) ARX788, which is currently in Phase I trials in Australia and New Zealand.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES